Evidence map›Paper›PMID 35439935›Full record

ArticleBMC bioinformatics2022

Integrative analysis of mutated genes and mutational processes reveals novel mutational biomarkers in colorectal cancer.

Hamed Dashti, Iman Dehzangi, Masroor Bayati, James Breen, Amin Beheshti, Nigel Lovell, Hamid R Rabiee, Hamid Alinejad-Rokny

Abstract read
In one paragraph

Article in BMC bioinformatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. The Translational Research Program in Cancer Differences across Populations.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hamed Dashti *Bioinformatics and Computational Biology Lab, Department of Computer Engineering, Sharif University of Technology, 11365, Tehran, Iran.
Iman Dehzangi *Center for Computational and Integrative Biology (CCIB), Rutgers University, Camden, NJ, 08102, USA.
Masroor BayatiBioinformatics and Computational Biology Lab, Department of Computer Engineering, Sharif University of Technology, 11365, Tehran, Iran.
James BreenSouth Australian Health and Medical Research Institute, Adelaide, SA, 5000, Australia.
Amin BeheshtiDepartment of Computing, Macquarie University, Sydney, NSW, 2109, Australia.
Nigel LovellTyree Institute of Health Engineering and The Graduate School of Biomedical Engineering, UNSW Sydney, Sydney, NSW, 2052, Australia.
Hamid R RabieeBioinformatics and Computational Biology Lab, Department of Computer Engineering, Sharif University of Technology, 11365, Tehran, Iran. RABIEE@sharif.edu.
Hamid Alinejad-RoknyBioMedical Machine Learning Lab, The Graduate School of Biomedical Engineering, UNSW Sydney, Sydney, NSW, 2052, Australia. h.alinejad@ieee.org.

Funding

University of New South Wales p23542
6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. Recent studies have observed causative mutations in susceptible genes related to colorectal cancer in 10 to 15% of the patients. This highlights the importance of identifying mutations for early detection of this cancer for more effective treatments among high risk individuals. Mutation is considered as the key point in cancer research. Many studies have performed cancer subtyping based on the type of frequently mutated genes, or the proportion of mutational processes. However, to the best of our knowledge, combination of these features has never been used together for this task. This highlights the potential to introduce better and more inclusive subtype classification approaches using wider range of related features to enable biomarker discovery and thus inform drug development for CRC.

resultsIn this study, we develop a new pipeline based on a novel concept called 'gene-motif', which merges mutated gene information with tri-nucleotide motif of mutated sites, for colorectal cancer subtype identification. We apply our pipeline to the International Cancer Genome Consortium (ICGC) CRC samples and identify, for the first time, 3131 gene-motif combinations that are significantly mutated in 536 ICGC colorectal cancer samples. Using these features, we identify seven CRC subtypes with distinguishable phenotypes and biomarkers, including unique cancer related signaling pathways, in which for most of them targeted treatment options are currently available. Interestingly, we also identify several genes that are mutated in multiple subtypes but with unique sequence contexts.

conclusionOur results highlight the importance of considering both the mutation type and mutated genes in identification of cancer subtypes and cancer biomarkers. The new CRC subtypes presented in this study demonstrates distinguished phenotypic properties which can be effectively used to develop new treatments. By knowing the genes and phenotypes associated with the subtypes, a personalized treatment plan can be developed that considers the specific phenotypes associated with their genomic lesion.

Indexed as

Colorectal NeoplasmsBiomarkers, TumorGenomicsHumansMutationPhenotypeBiomarkers, TumorCancer subtype identificationColorectal cancerGene prioritizationMotif analysisPersonalized medicineSomatic point mutationsTherapeutic targets

Identifiers

PMID35439935
PMCPMC9017053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.